香港股市 已收市

DXCM Nov 2024 130.000 call

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
5.100.00 (0.00%)
市場開市。 截至 10:26AM EDT。
全螢幕
前收市價5.10
開市5.10
買盤4.20
賣出價4.50
拍板130.00
到期日2024-11-15
今日波幅5.10 - 5.10
合同範圍
成交量2
未平倉合約563
  • Zacks

    DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands

    DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.

  • Zacks

    Insulet (PODD) Unveils Key Achievements for the Omnipod 5 System

    Insulet (PODD) debuts the Omnipod 5 AID system in France and announces new updates for the U.S. markets.

  • InvestorPlace

    The 3 Best Diabetes Stocks to Buy in June 2024

    Since last October, there has been a marked reduction in fears about the sales of diabetes drugs dropping as a result weight-loss drugs. That’s because Dexcom (NASDAQ:DXCM) delivered stronger-than-expected third-quarter results in October. And during its Q3 earnings call, Dexcom actually reported that when diabetes patients are on the GLP-1 drugs, their demand for glucose monitors tend to rise. Dexcom and other diabetes stocks advanced significantly over the subsequent six months or so, but they